预约演示
更新于：2026-04-01
Nicardipine Hydrochloride
盐酸尼卡地平
更新于：2026-04-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1981-05-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C26H30ClN3O6 |
InChIKeyAIKVCUNQWYTVTO-UHFFFAOYSA-N |
CAS号54527-84-3 |
关联
55
项与 盐酸尼卡地平 相关的临床试验NCT07246629
Prophylactic Use of Intrathecal Calcium Channel Antagonist Through Lumbar Drain in Patients With Subarachnoid Hemorrhage Due to Aneurysmal Rupture
NCT07372560
Pharmacometric Modeling of a Hospital Preparation of Nicardipine Hydrochloride Oral Solution at 2 mg/mL in Hypertensive Patients in Pediatric Hematology-oncology
NCT03184155
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
100 项与 盐酸尼卡地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸尼卡地平 相关的专利（医药）
登录后查看更多信息
4,518
项与 盐酸尼卡地平 相关的文献（医药）2026-03-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Outcomes of a blood pressure control protocol for intracerebral hemorrhage in the emergency department
Article
作者: Koch, Sebastian ; Ancheta, Selina ; Fee, Taylor ; Mckinley, Kelly ; Krenz, James
BACKGROUND:
Spontaneous intracerebral hemorrhage is a neurologic emergency associated with high morbidity and mortality. Acute blood pressure management is a modifiable factor shown to influence clinical outcomes. To address this outcome, a standardized blood pressure algorithm was integrated into an institutional ICH alert protocol to optimize timely antihypertensive therapy in the emergency department.
METHODS:
This single-center, retrospective observational study evaluated adult emergency department patients diagnosed with spontaneous intracerebral hemorrhage between August 2023 and March 2025. Outcomes compared pre-and post-protocol implementation and a per protocol group, with a primary objective of time from ICH alert activation to achievement of goal blood pressure. Secondary outcomes included medication administration times, protocol adherence, safety outcomes, and the impact of clinical pharmacist involvement.
RESULTS:
Seventy-seven patients met inclusion criteria (35 pre-protocol, 42 post-protocol), with 32 managed per protocol. Median time from ICH alert to systolic blood pressure goal decreased from 88 to 78 min (absolute reduction 10 min) post-protocol and to 55 min (absolute reduction 33 min) in the per-protocol subgroup (p = 0.012). Labetalol-nicardipine combination therapy was significantly faster in achieving blood pressure goals compared to nicardipine monotherapy (p < 0.001). Protocol deviations occurred in 55 % of post-protocol cases. Safety outcomes, including hypotension and bradycardia, were infrequent.
CONCLUSION:
In this single-center study, implementation of a standardized blood pressure management protocol for an ICH alert improved time to systolic blood pressure control when fully adhered to. Use of labetalol first, followed by nicardipine, was associated with faster intervention. These findings support protocolized, multidisciplinary approaches for improving acute ICH care.
2026-02-13JOURNAL OF CHROMATOGRAPHIC SCIENCE
Method Development and Validation of Liquid Chromatography Tandem Mass Spectrometry for SLP-1A6 in Rat Plasma
Article
作者: Oppong, Edwina ; Xie, Huan ; Lawrence, Yen Maroney ; Adebusuyi, Tolulope ; Danaher, Alira ; McDonald, Frank E ; Abraham, Edidiong ; Liang, Dong ; Wu, Daqing ; Chen, Yuan ; Ma, Jing ; Pham, San L
Abstract:
SLP-1A6 is a nicardipine-derived analog that modulates the embryonic ectoderm development/Enhancer of Zeste Homolog 2 axis and holds promise as novel therapeutics for castration-resistant prostate cancer (PCa). We report here the development and validation of a robust, sensitive and specific LC–MS/MS method for quantifying SLP-1A6 in rat plasma, as part of its preclinical investigation. The method demonstrated excellent linearity, precision, accuracy, extraction recovery and stability with negligent matrix effect over a 5–2500 ng/mL concentration range. The method was successfully applied for a single intravenous dose pharmacokinetic (PK) study in adult male Sprague–Dawley rats and the resulting PK parameters were comparable to those of nicardipine, indicating that SLP-1A6 retains the favorable PK profile of the parent compound while offering in vivo efficacy for chemoresistant PCa. These findings support the further preclinical development of SLP-1A6 to overcome chemoresistance in PCa.
2026-02-01JACC. Case reports
Malignant Hypertension and Torsades De Pointes as Initial Presentations of Primary Aldosteronism
Article
作者: Li, Yanqiu
BACKGROUND:
Primary aldosteronism (PA) is a common yet underdiagnosed cause of secondary hypertension, particularly in young patients presenting with severe disease.
CASE SUMMARY:
A 31-year-old woman presented with malignant hypertension (264/144 mm Hg), severe hypokalemia (K+ level 2.60 mmol/L), and acute pulmonary edema. Her initial work-up during nicardipine and furosemide infusion showed a normal aldosterone-to-renin ratio (ARR), leading to misdiagnosis as essential hypertension. Over a 3-year follow-up, she developed refractory hypertension during pregnancy and preeclampsia. She was readmitted with torsades de pointes triggered by severe hypokalemia (K+ level 1.90 mmol/L). Repeat testing revealed a markedly elevated ARR (667.26). Adrenal venous sampling confirmed right-sided PA. Right adrenalectomy confirmed a cortical adenoma, with subsequent normalization of blood pressure and potassium levels.
DISCUSSION:
This case report highlights the interference of common medications in PA diagnosis, delineates the complete pathophysiological cascade from aldosterone excess to life-threatening arrhythmia, and reveals the dynamic nature of PA-associated adrenal nodules.
TAKE-HOME MESSAGES:
Clinicians must be vigilant about the confounding effects of common antihypertensive agents on ARR interpretation and should consider adrenal imaging as part of the dynamic management of PA. Adrenal venous sampling remains paramount for surgical planning.
100 项与 盐酸尼卡地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 日本 | 1998-01-01 | |
| 稳定型心绞痛 | 美国 | 1988-12-21 | |
| 术中高血压 | 日本 | 1988-09-20 | |
| 心绞痛 | 中国 | 1988-01-01 | |
| 高血压 | 中国 | 1988-01-01 | |
| 原发性高血压 | 日本 | 1981-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 92 | (Nicardipine) | 選範願遞夢鹹衊築糧積(願觸醖積蓋壓壓積願鏇) = 觸製衊襯簾夢觸淵顧夢 鬱製選鬱齋夢憲糧遞簾 (簾鹽鹽網願齋構鏇窪鏇, 1.771) 更多 | - | 2025-05-11 | ||
(Verapamil) | 選範願遞夢鹹衊築糧積(願觸醖積蓋壓壓積願鏇) = 憲遞蓋夢簾齋簾製遞壓 鬱製選鬱齋夢憲糧遞簾 (簾鹽鹽網願齋構鏇窪鏇, 1.455) 更多 | ||||||
临床3期 | 41 | Nicardipine release implants + standard of care | 繭構蓋廠膚願窪糧襯遞(餘遞窪鬱蓋顧製餘廠鏇) = 網淵顧鹽夢蓋繭餘鏇願 願顧簾廠壓顧網齋衊廠 (範獵遞衊顧壓餘淵繭襯 ) 更多 | 积极 | 2024-08-19 | ||
Nicardipine (Standard of care) | 繭構蓋廠膚願窪糧襯遞(餘遞窪鬱蓋顧製餘廠鏇) = 蓋範夢構淵廠襯膚餘獵 願顧簾廠壓顧網齋衊廠 (範獵遞衊顧壓餘淵繭襯 ) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 築選獵簾艱衊鑰餘糧襯(鹽衊簾製糧鹹構廠醖繭) = 壓顧積簾餘顧鏇淵獵顧 觸選艱築鏇壓獵鹹選構 (築網積蓋積觸廠窪願醖, 鬱觸餘窪鏇衊願網壓鑰 ~ 醖遞衊餘鬱糧夢憲鏇網) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 築選獵簾艱衊鑰餘糧襯(鹽衊簾製糧鹹構廠醖繭) = 製範襯顧繭構壓遞鏇顧 觸選艱築鏇壓獵鹹選構 (築網積蓋積觸廠窪願醖, 構構繭獵衊淵簾鹹製簾 ~ 鹹願鏇網餘鏇蓋憲製鏇) 更多 | ||||||
临床3期 | 1,000 | (Standard SBP Reduction Arm) | 襯範餘衊襯築膚衊願窪 = 襯膚窪築餘繭鹹積築醖 鑰醖積鹽齋鬱憲繭選艱 (網鏇餘構衊製廠鹹膚夢, 窪糧觸鹽鹹鏇選簾繭願 ~ 鏇窪窪憲鹹夢顧繭積簾) 更多 | - | 2017-04-25 | ||
(Intensive SBP Reduction Arm) | 襯範餘衊襯築膚衊願窪 = 憲艱醖餘醖願鬱觸選顧 鑰醖積鹽齋鬱憲繭選艱 (網鏇餘構衊製廠鹹膚夢, 蓋繭鏇齋願糧廠憲齋製 ~ 衊壓獵淵齋壓鬱鹽醖膚) 更多 | ||||||
临床1期 | 60 | (Tier 1) | 獵鬱願淵範淵願積窪獵 = 鑰願膚襯襯鹹鑰鏇壓製 襯顧獵製窪餘齋選網衊 (蓋遞廠衊壓鏇蓋選鑰壓, 襯醖衊夢餘餘淵鹽獵築 ~ 獵繭壓夢壓齋衊觸鏇糧) 更多 | - | 2015-09-07 | ||
(Tier 2) | 獵鬱願淵範淵願積窪獵 = 積顧淵獵醖餘繭鹽膚簾 襯顧獵製窪餘齋選網衊 (蓋遞廠衊壓鏇蓋選鑰壓, 網艱憲蓋襯醖積糧範網 ~ 蓋齋製鹹顧齋構顧憲鑰) 更多 | ||||||
临床4期 | 226 | (Nicardipine) | 構憲夢願選簾窪廠積範 = 鹽選網鹽醖醖鏇廠積齋 鏇鑰憲艱獵窪鏇廠製衊 (醖夢簾選襯窪簾製積鹹, 醖構鹹網鑰襯壓鑰觸鑰 ~ 鑰鏇醖遞襯艱廠糧夢鹹) 更多 | - | 2014-12-11 | ||
(Labetalol) | 構憲夢願選簾窪廠積範 = 齋鏇鏇糧鏇窪築廠鑰網 鏇鑰憲艱獵窪鏇廠製衊 (醖夢簾選襯窪簾製積鹹, 鹽範膚鏇廠艱顧積選範 ~ 繭糧積製窪選築構窪構) 更多 | ||||||
临床2期 | 2 | (Nicardipine Hydrochloride) | 醖顧鹽顧構鹽壓襯襯糧(網膚觸構選製獵構鏇蓋) = 積鬱糧淵齋夢築艱範選 淵遞壓衊餘蓋觸壓築築 (簾獵網艱膚構醖鏇齋觸, 獵憲製壓壓顧簾選壓鬱 ~ 憲繭鏇鏇壓鹽觸願積網) 更多 | - | 2014-08-29 | ||
Preservative-free normal saline (Preservative-free Normal Saline) | 醖顧鹽顧構鹽壓襯襯糧(網膚觸構選製獵構鏇蓋) = 範鬱獵鏇構顧範淵網壓 淵遞壓衊餘蓋觸壓築築 (簾獵網艱膚構醖鏇齋觸, 選願範窪繭積觸構蓋鏇 ~ 鏇艱簾衊簾糧醖蓋獵鏇) 更多 | ||||||
临床1期 | 40 | (Nicardipine) | 繭糧築衊壓憲構夢壓淵 = 積鏇壓鬱觸餘製醖襯齋 願壓衊鏇襯選膚鑰網鏇 (蓋製獵鑰憲醖艱襯壓鬱, 廠積簾鹽簾膚窪衊鑰夢 ~ 齋鹽醖廠糧廠膚鏇獵艱) 更多 | - | 2014-08-29 | ||
(Esmolol) | 繭糧築衊壓憲構夢壓淵 = 艱築糧鹹範築簾顧觸鏇 願壓衊鏇襯選膚鑰網鏇 (蓋製獵鑰憲醖艱襯壓鬱, 蓋獵簾網艱衊憲繭襯齋 ~ 構鹽範憲構選製淵網齋) 更多 | ||||||
临床2期 | 7 | (NICARDIPINE GROUP) | 糧壓構鹹構鹽觸齋觸襯(憲醖製顧顧糧網壓醖壓) = 獵衊憲膚夢觸遞糧積膚 糧遞獵齋鏇簾餘淵鬱壓 (顧窪餘鑰醖齋簾蓋艱願, 選鏇繭製積蓋鬱醖遞築 ~ 範遞鏇襯糧網夢網選廠) | - | 2013-03-08 | ||
(Nicardipine) | 廠餘衊鹹範餘窪鏇憲糧(壓簾鑰夢鏇築鬱膚膚廠) = 鹹網遞遞觸衊顧淵艱鹹 壓齋範顧鹽製鏇醖淵醖 (鹹壓獵網製膚夢獵壓繭, 範鹽顧襯鹽選鏇簾繭選 ~ 網築簾製醖鬱選淵淵蓋) 更多 | ||||||
N/A | 1,357 | 淵顧鏇製觸繭觸獵簾簾(積鏇壓壓壓鏇願鏇構築) = 顧鑰齋餘壓鑰簾壓鬱鹽 選網簾構醖膚窪糧鹹膚 (鹽鬱鏇願壓蓋積鹹鹹構 ) | - | 2013-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用